Comparing two aspirin doses with a P2Y12 inhibitor after a coronary stent procedure
Compares 50 mg and 100 mg aspirin in adults after coronary stenting.
Plain-language title generated from the registry record
Registry title: Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
Key facts
- Where
- Changchun, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 85 with coronary artery disease who have had a successful stent procedure (PCI) and plan at least 12 months of aspirin plus a P2Y12 inhibitor.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Acute coronary syndrome or chronic coronary syndrome, treated with a successful PCI with stent implantation.
- Earlier treatment
- Must have had a successful PCI with a stent. Must plan at least 12 months of dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) after PCI. Cannot have joined another interventional trial within 30 days before screening.
Main reasons for not taking part
- Known allergy or contraindication to aspirin, P2Y12 inhibitors, or related excipients
- High bleeding risk, such as brain bleeding ever, stomach or gut bleeding within 6 months, or a bleeding or clotting disorder
- Severe liver problems (Child-Pugh class C) or severe kidney problems (eGFR < 30 mL/min/1.73 m²)
- Stroke within 3 months before enrollment
- Pregnant or breastfeeding women
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07846462, who can take part
Where in China
- First Hospital of Jilin UniversityChangchun, ChinaContact: Qian Tong, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jilin University
- Trial code
- NCT07846462
- Record updated
- 1 October 2026
- Original description
This is a randomized, open-label, active-controlled, non-inferiority clinical trial (the ASPIRE-LD trial) conducted in China. It aims to compare the efficacy and safety of low-dose aspirin (50 mg once daily) versus standard-dose aspirin (100 mg once daily), both in combination with a P2Y12 inhibitor, in patients who have successfully undergone percutaneous coronary intervention (PCI) and plan to receive at least 12 months of dual antiplatelet therapy (DAPT).Read full original descriptionShow less
The Efficacy and Safety of Aspirin 50mg Versus 100mg in Combination With a P2Y12 Inhibitor After Percutaneous Coronary Intervention: A Randomized, Open-label, Active-controlled, Non-inferiority Trial
This is a randomized, open-label, active-controlled, non-inferiority clinical trial (the ASPIRE-LD trial) conducted in China. It aims to compare the efficacy and safety of low-dose aspirin (50 mg once daily) versus standard-dose aspirin (100 mg once daily), both in combination with a P2Y12 inhibitor, in patients who have successfully undergone percutaneous coronary intervention (PCI) and plan to receive at least 12 months of dual antiplatelet therapy (DAPT).
A total of 2640 eligible patients will be randomly assigned in a 1:1 ratio to receive either 50 mg or 100 mg of enteric-coated aspirin daily, plus a P2Y12 inhibitor (ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily, prescribed according to routine clinical practice). All participants will be followed for 12 months after randomization.
The primary goal is to verify that 50 mg aspirin is non-inferior to the 100 mg standard dose in preventing major adverse cardiac and cerebrovascular events (MACCE: cardiovascular death, non-fatal myocardial infarction, definite/probable stent thrombosis, and ischemic stroke) at 12 months post-PCI. If non-inferiority is confirmed, the study will further test whether 50 mg aspirin reduces clinically relevant bleeding events (BARC type 2, 3, or 5) better than the standard dose.
The study is sponsored by the First Hospital of Jilin University and will be carried out in 10-15 tertiary hospitals across China. Its findings will provide evidence for optimizing aspirin dosing in post-PCI DAPT.
Inclusion: Aged 18 to 85 years at the time of screening; Diagnosed with acute coronary syndrome (ACS) or chronic coronary syndrome (CCS); Has undergone successful percutaneous coronary intervention (PCI) with stent implantation; Planned to receive at least 12 months of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor after PCI; Able to provide written informed consent and comply with study follow-up requirements.
Exclusion: Ischemic or hemorrhagic stroke within 3 months before enrollment; Participation in another interventional clinical trial within 30 days before screening; Known hypersensitivity or contraindication to aspirin, P2Y12 inhibitors, or related excipients; High bleeding risk: history of intracranial hemorrhage, gastrointestinal bleeding within 6 months, active bleeding diathesis, or coagulopathy; Life expectancy < 12 months due to other severe comorbidities such as advanced malignancy; Any other condition judged by the investigator to make the patient unsuitable for the study; Severe hepatic dysfunction (Child-Pugh class C) or severe renal impairment (eGFR < 30 mL/min/1.73 m²); Pregnant or lactating women; women of childbearing potential unwilling to use effective contraception.